株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子検査の世界市場の予測:DTC遺伝子診断、出生前遺伝子検査、予測遺伝子検査、ファーマコゲノミクス (薬理ゲノミクス)

The Global Genetic Testing Market By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts with Executive and Consultant Guides 2020 to 2024

発行 Howe Sound Research 商品コード 384217
出版日 ページ情報 英文 438 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.71円で換算しております。
Back to Top
遺伝子検査の世界市場の予測:DTC遺伝子診断、出生前遺伝子検査、予測遺伝子検査、ファーマコゲノミクス (薬理ゲノミクス) The Global Genetic Testing Market By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts with Executive and Consultant Guides 2020 to 2024
出版日: 2019年10月02日 ページ情報: 英文 438 Pages
概要

当レポートでは、世界の遺伝子検査市場について調査分析し、14ヶ国・5地域を対象に、検査価格、数量予測、市場予測などについて、体系的な情報を提供しています。

第1章 イントロダクションと市場定義

  • 遺伝子検査の定義
  • ゲノミクス革命
  • 市場定義
  • 米国の医療市場・臨床検査:見通し

第2章 市場概要

  • 市場参入企業のさまざまな役割
    • サプライヤー/医薬品
    • 独立系ラボ (特殊/専門)
    • 独立系ラボ (国/地域)
    • 独立系ラボ (解析)
    • 公的ラボ (国/地域)
    • 病院ラボ
    • 診療所ラボ
    • DTCラボ
    • 独立系遺伝子検査ラボ
    • 監査団体
  • 遺伝子検査:種類、例、考察
    • 着床前遺伝子診断:新興市場
    • 出生前診断:新技術が生み出す機会
    • 新生児スクリーニング
    • 診断検査
    • キャリア検査
    • 予測/発症前検査
    • ファーマコゲノミクス (薬理ゲノミクス)
    • 法医学検査
    • 親子鑑定
    • 祖先遺伝子検査
  • 産業構造
    • 病院検査のシェア
    • 規模の経済性
    • 診療所ラボ
    • 診療所・POC検査
  • 主要企業のプロファイル
    • 23andME Inc.
    • Abbott Diagnostics
    • Adaptive Biotechnologies
    • Admera Health, LLC
    • Agena Bioscience, Inc
    • Agilent
    • Akonni Biosystems
    • Ancestry.com LLC
    • Anchor Dx
    • ArcherDx, Inc.
    • ARUP Laboratories
    • Asuragen
    • Beckman Coulter, Inc
    • Becton, Dickinson and Company
    • BGI Genomics Co. Ltd
    • Bioarray Genetics
    • Biocept, Inc.
    • Biodesix Inc.
    • BioFluidica
    • BioGenex
    • Biolidics Ltd
    • bioMerieux Diagnostics
    • Bioneer Corporation
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne
    • Cancer Genetics
    • Caris Molecular Diagnostics
    • CellMax Life
    • Centogene
    • Cepheid (現:Danaher)
    • Chronix Biomedical
    • Circulogene
    • Clinical Genomics
    • Complete Genomics, Inc. - A BGI Company
    • Cynvenio
    • Dante Labs
    • Datar Cancer Genetics Limited
    • Diasorin S.p.A.
    • Epic Sciences
    • Epigenomics AG
    • Eurofins Scientific
    • Excellerate Bioscience
    • Exosome Diagnostics
    • Fabric Genomics
    • Fluidigm Corp
    • Foundation Medicine
    • Freenome
    • 富士フイルム和光純薬
    • 富士レビオ
    • GE Healthcare Life Sciences
    • Gene by Gene, Ltd.
    • Genedrive
    • GeneFirst Ltd.
    • Genetron Health (Beijing) Co., Ltd.
    • Genomic Health
    • Genomics England
    • Genomics Personalized Health (GPH)
    • GenomOncology
    • Genzyme Corporation
    • Grail, Inc.
    • Grifols
    • Guardant Health
    • Guardiome
    • HeiScreen
    • Helix
    • Helomics
    • Hologic
    • Horizon Discovery
    • HTG Molecular Diagnostics
    • Human Longevity, Inc.
    • iCellate
    • Illumina
    • Incell Dx
    • Inivata
    • Integrated Diagnostics
    • Invitae Corporation
    • Invivoscribe
    • Karius
    • MDNA Life SCIENCES, Inc.
    • MDx Health
    • Medgenome
    • Meridian Bioscience
    • Mesa Biotech
    • MIODx
    • miR Scientific
    • MNG Labs
    • Molecular MD
    • NantHealth, Inc.
    • Natera
    • NeoGenomics
    • New Oncology
    • Novogene Bioinformatics Technology Co., Ltd.
    • Omega Bioservices
    • OncoDNA
    • ORIG3N, Inc.
    • Origene Technologies
    • Oxford Nanopore Technologies
    • Pacific Biosciences
    • Panagene
    • Perkin Elmer
    • Personal Genome Diagnostics
    • Personalis
    • Precipio
    • PrecisionMed
    • Promega
    • Protagen Diagnostics
    • Qiagen Gmbh
    • Quantumdx
    • Resolution Biosciences, Inc
    • Roche Molecular Diagnostics
    • Seegene
    • Sequencing.com
    • Siemens Healthineers
    • simfo GmbH
    • Singlera Genomics Inc.
    • SkylineDx
    • Stratos Genomics
    • Sure Genomics, Inc.
    • Sysmex
    • Sysmex Inostics
    • Tempus Labs, Inc.
    • Thermo Fisher Scientific Inc.
    • Veritas Genetics
    • Volition
  • 主要企業の市場シェア:分析

第3章 市場動向

  • 成長促進要因
  • 成長阻害要因
  • 検査装置・自動化
  • 診断技術の発展

第4章 遺伝子検査の最近の発展

第5章 国別市場規模:北米

  • 米国
  • カナダ

第6章 国別市場:欧州

  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • ロシア
  • その他の欧州、旧ソ連

第7章 国別市場:アジア太平洋地域

  • 中国
  • 日本
  • 韓国
  • インド
  • オーストラリア
  • その他のアジア太平洋地域

第8章 国別市場:ラテンアメリカ、アフリカ・中東

  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • アフリカ・中東

第9章 世界市場のサマリー

  • 世界市場

第10章 遺伝子検査の将来

付録

図表

Table of Tables

  • Table 1: Most Common Traditional Genetic Disorders
  • Table 2: Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Million)
  • Table 3: Market Players by Type
  • Table 4: The Different Types of Genetic Tests
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies-Speed and Cost
  • Table 9: USA Prenatal and Newborn - Volume Price and Revenue Forecast
  • Table 10: USA Predictive - Volume Price and Revenue Forecast
  • Table 11: USA Pharmacogenomic Testing - Volume Price and Revenue Forecast
  • Table 12: USA Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 13: USA All Genetic testing - Volume Price and Revenue Forecast
  • Table 14: Canada Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 15: Canada Predictive Testing - Volume Price and Revenue Forecast
  • Table 16: Canada Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 17: Canada Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 18: Canada All Genetic testing - Volume Price and Revenue Forecast
  • Table 19: France Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 20: France Predictive Testing - Volume Price and Revenue Forecast
  • Table 21: France Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 22: France Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 23: France All Genetic testing - Volume Price and Revenue Forecast
  • Table 24: Germany Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 25: Germany Predictive Testing - Volume Price and Revenue Forecast
  • Table 26: Germany Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 27: Germany Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 28: Germany All Genetic testing - Volume Price and Revenue Forecast
  • Table 29: U.K. Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 30: U.K. Predictive Testing - Volume Price and Revenue Forecast
  • Table 31: U.K. Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 32: U.K. Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 33: U.K. All Genetic testing - Volume Price and Revenue Forecast
  • Table 34: Spain Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 35: Spain Predictive Testing - Volume Price and Revenue Forecast
  • Table 36: Spain Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 37: Spain Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 38: Spain All Genetic testing - Volume Price and Revenue Forecast
  • Table 39: Italy Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 40: Italy Predictive Testing - Volume Price and Revenue Forecast
  • Table 41: Italy Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 42: Italy Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 43: Italy All Genetic testing - Volume Price and Revenue Forecast
  • Table 44: Russia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 45: Russia Predictive Testing - Volume Price and Revenue Forecast
  • Table 46: Russia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 47: Russia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 48: Russia All Genetic testing - Volume Price and Revenue Forecast
  • Table 49: Rest of Europe Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 50: Rest of Europe Predictive Testing - Volume Price and Revenue Forecast
  • Table 51: Rest of Europe Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 52: Rest of Europe Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 53: Rest of Europe All Genetic testing - Volume Price and Revenue Forecast
  • Table 54: China Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 55: China Predictive Testing - Volume Price and Revenue Forecast
  • Table 56: China Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 57: China Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 58: China All Genetic testing - Volume Price and Revenue Forecast
  • Table 59: Japan Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 60: Japan Predictive Testing - Volume Price and Revenue Forecast
  • Table 61: Japan Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 62: Japan Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 63: Japan All Genetic testing - Volume Price and Revenue Forecast
  • Table 64: South Korea Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 65: South Korea Predictive Testing - Volume Price and Revenue Forecast
  • Table 66: South Korea Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 67: South Korea Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 68: South Korea All Genetic testing - Volume Price and Revenue Forecast
  • Table 69: India Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 70: India Predictive Testing - Volume Price and Revenue Forecast
  • Table 71: India Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 72: India Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 73: India All Genetic testing - Volume Price and Revenue Forecast
  • Table 74: Australia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 75: Australia Predictive Testing - Volume Price and Revenue Forecast
  • Table 76: Australia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 77: Australia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 78: Australia All Genetic testing - Volume Price and Revenue Forecast
  • Table 79: Rest of Asia Pacific Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 80: Rest of Asia Pacific Predictive Testing - Volume Price and Revenue Forecast
  • Table 81: Rest of Asia Pacific Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 82: Rest of Asia Pacific Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 83: Rest of Asia Pacific All Genetic testing - Volume Price and Revenue Forecast
  • Table 84: Brazil Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 85: Brazil Predictive Testing - Volume Price and Revenue Forecast
  • Table 86: Brazil Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 87: Brazil Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 88: Brazil All Genetic testing - Volume Price and Revenue Forecast
  • Table 89: Mexico Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 90: Mexico Predictive Testing - Volume Price and Revenue Forecast
  • Table 91: Mexico Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 92: Mexico Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 93: Mexico All Genetic testing - Volume Price and Revenue Forecast
  • Table 94: Rest of Latin America Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 95: Rest of Latin America Predictive Testing - Volume Price and Revenue Forecast
  • Table 96: Rest of Latin America Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 97: Rest of Latin America Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 98: Rest of Latin America All Genetic testing - Volume Price and Revenue Forecast
  • Table 99: Africa & Middle East Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 100: Africa & Middle East Predictive Testing - Volume Price and Revenue Forecast
  • Table 101: Africa & Middle East Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 102: Africa & Middle East Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 103: Africa & Middle East All Genetic testing - Volume Price and Revenue Forecast
  • Table 104: Global Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 105: Global Predictive Testing - Volume Price and Revenue Forecast
  • Table 106: Global Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 107: Global Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 108: Global All Genetic testing - Volume Price and Revenue Forecast
  • Table 109: 2019 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2: Chart of 2017 Market Shares of Key Genetic Testing Companies
  • Figure 3: Top Ten Sequencing Companies
  • Figure 4: Percentage of World Population Over 65
目次

OVERVIEW:

Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

Our facts and support = Your success.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Genetic Testing Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Genetic Testing Definition in This Report
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Volumes
    • 1.3.2. Prices
    • 1.3.3. Revenue Market Size
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for laboratory testing

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Supplier/pharmaceutical
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Independent Genetic Testing Lab
    • 2.1.10. Audit Body
  • 2.2. Genetic Tests - Types, Examples and Discussion
    • 2.2.1. Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2. Prenatal Diagnosis-New Technologies Create Opportunity
    • 2.2.3. Newborn Screening
    • 2.2.2. Diagnostic Testing
    • 2.2.3. Carrier Testing
    • 2.2.6. Predictive and Presymptomatic Testing
    • 2.2.7. Pharmacogenomics
    • 2.2.8. Forensic Testing
    • 2.2.9. Parental Testing
    • 2.2.10. Ancestral Testing
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
  • 2.3.2.1. Hospital vs. Central Lab
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Profiles of Key Companies
    • 23andME Inc
    • Abbott Diagnostics
    • Adaptive Biotechnologies
    • Admera Health, LLC
    • Agena Bioscience, Inc
    • Agilent
    • Akonni Biosystems
    • Ancestry.com LLC
    • Anchor Dx
    • ArcherDx, Inc.
    • ARUP Laboratories
    • Asuragen
    • Beckman Coulter, Inc.
    • Becton, Dickinson and Company
    • BGI Genomics Co. Ltd
    • Bioarray Genetics
    • Biocept, Inc
    • Biodesix Inc.
    • BioFluidica
    • BioGenex
    • Biolidics Ltd
    • bioMérieux Diagnostics
    • Bioneer Corporation
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne
    • Cancer Genetics
    • Caris Molecular Diagnostics
    • CellMax Life
    • Centogene
    • Cepheid (now Danaher)
    • Chronix Biomedical
    • Circulogene
    • Clinical Genomics
    • Complete Genomics, Inc.-A BGI Company
    • Cynvenio
    • Dante Labs
    • Datar Cancer Genetics Limited
    • Diasorin S.p.A.
    • Epic Sciences
    • Epigenomics AG
    • Eurofins Scientific
    • Excellerate Bioscience
    • Exosome Diagnostics
    • Fabric Genomics
    • Fluidigm Corp
    • Foundation Medicine
    • Freenome
    • FUJIFILM Wako Diagnostics
    • Fujirebio
    • GE Healthcare Life Sciences
    • Gene by Gene, Ltd.
    • Genedrive
    • GeneFirst Ltd
    • Genetron Health (Beijing) Co., Ltd.
    • Genomic Health
    • Genomics England
    • Genomics Personalized Health (GPH)
    • GenomOncology
    • Genzyme Corporation
    • Grail, Inc
    • Grifols
    • Guardant Health
    • Guardiome
    • HeiScreen
    • Helix
    • Helomics
    • Hologic
    • Horizon Discovery
    • HTG Molecular Diagnostics
    • Human Longevity, Inc.
    • iCellate
    • Illumina
    • Incell Dx
    • Inivata
    • Integrated Diagnostics
    • Invitae Corporation
    • Invivoscribe
    • Karius
    • MDNA Life SCIENCES, Inc
    • MDx Health
    • Medgenome
    • Meridian Bioscience
    • Mesa Biotech
    • MIODx
    • miR Scientific
    • MNG Labs
    • Molecular MD
    • NantHealth, Inc.
    • Natera
    • NeoGenomics
    • New Oncology
    • Novogene Bioinformatics Technology Co., Ltd
    • Omega Bioservices
    • OncoDNA
    • ORIG3N, Inc.
    • Origene Technologies
    • Oxford Nanopore Technologies
    • Pacific Biosciences
    • Panagene
    • Perkin Elmer
    • Personal Genome Diagnostics
    • Personalis
    • Precipio
    • PrecisionMed
    • Promega
    • Protagen Diagnostics
    • Qiagen Gmbh
    • Quantumdx
    • Resolution Biosciences, Inc
    • Roche Molecular Diagnostics
    • Seegene
    • Sequencing.com
    • Siemens Healthineers
    • simfo GmbH
    • Singlera Genomics Inc
    • SkylineDx
    • Stratos Genomics
    • Sure Genomics, Inc.
    • Sysmex
    • Sysmex Inostics
    • Tempus Labs, Inc.
    • Thermo Fisher Scientific Inc
    • Veritas Genetics
    • Volition
  • 2.5. Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2. Aging Population a Boon for Diagnostics
    • 3.1.3. Pharmacogenomics Drives Further Growth.
    • 3.1.4. Oncology and Liquid Biopsy Enter New Era
    • 3.1.5. Fertility Practice Growth drives market
    • 3.1.6. Direct to Consumer begins to break out
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Testing usage analysis curtailing growth.
    • 3.2.4. Wellness has a downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution.
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. POCT/Self Testing Disruptive Force
    • 3.4.4. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5. CGES Testing, A Brave New World
    • 3.4.6. Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1. Importance of This Section
  • 4.1.2. How to Use This Section
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study
    • Qiagen, NeuMoDx Ink Partnership, Merger Agreement
    • Prenetics Acquires DNAFit for $10M
    • Myriad Genetics to Acquire Counsyl for $375M
    • Roche inks $2.4B deal to buy out Foundation Medicine
    • Rapid genome sequencing could revolutionize health care
    • Future goal in UK is for every cancer patient to have his or her whole genome sequenced
    • Human Longevity Launches Whole Genome Product, MassMutual Partnerships
    • Influence of Whole Genome Sequencing growing
    • $1500 to sequence newborns in China
    • Scientists discover new nanoparticle, dubbed exomeres, released by tumors
    • New DNA tests look for 190 diseases in newborn's genetic code
    • Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia
    • New genetic risk score could help guide screening decisions for prostate cancer
    • Tele-genetics pilot makes genetic counseling accessible
    • Digital Genetic Assistant OptraGURU™ Launches Today From Optra Health
    • PacBridge Capital Partners Invests C$12M in Contextual Genomics
    • MDxHealth 2017 Revenues Rise 35 Percent on Prostate Cancer Tests
    • From DNA To Disease: A Diagnosis Made In Under A Day
    • A New Tool Uses CRISPR to Uncover Genetic Mutations
    • Sophia Genetics Gains CE-IVD Mark for Leukemia Assay
    • Novartis Completes Sale of Genoptix Lab Business
    • Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
    • PerkinElmer Launches Clinical Whole Genome Sequencing Services
    • WGS and AI help clinicians scale precision oncology
    • Veritas Genetics Buys Curoverse
    • Dante Labs Partners With Amazon UK for Special £349 Whole Genome Sequencing
    • Toolbox Genomics Launches Personalized Wellness App in Sequencing.com's Revolutionary
    • App Market
    • CDC invests in WGS to help states respond to infectious disease threats
    • IBM Watson impresses in WGS brain tumour analysis
    • OneOme, Genome.One Partner to Offer Genetic Risk, PGx Service in Australia
    • WGS aids in Salmonella outbreak control
    • CombiMatrix In Merger Agreement with Invitae to be Acquired for $33 Million in Invitae
    • Common Stock

5. Country Market Sizes-North America

  • 5.1. United States of America
    • 5.1.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 5.1.2. Predictive Testing-Volumes, Prices, Revenues
    • 5.1.3. Pharmacogenomic Testing-Volumes, Prices, Revenues
    • 5.1.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 5.1.5. All Genetic testing-Volumes, Prices, Revenues
  • 5.2. Canada
    • 5.2.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 5.2.2. Predictive Testing-Volumes, Prices, Revenues
    • 5.2.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 5.2.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 5.2.5. All Genetic testing-Volumes, Prices, Revenues

6. Country Markets-Europe

  • 6.1. France
    • 6.1.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.1.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.1.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.1.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.1.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.2. Germany
    • 6.2.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.2.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.2.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.2.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.2.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.3. United Kingdom
    • 6.3.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.3.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.3.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.3.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.3.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.4. Spain
    • 6.4.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.4.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.4.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.4.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.4.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.5. Italy
    • 6.5.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.5.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.5.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.5.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.5.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.6. Russia
    • 6.6.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.6.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.6.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.6.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.6.5. All Genetic testing-Volumes, Prices, Revenues
  • 6.7. Remainder of Europe and Former Soviet Union
    • 6.7.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 6.7.2. Predictive Testing-Volumes, Prices, Revenues
    • 6.7.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 6.7.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 6.7.5. All Genetic testing-Volumes, Prices, Revenues

7. Country Markets-Asia Pacific

  • 7.1. China
    • 7.1.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.1.2. Predictive Testing-Volumes, Prices, Revenues
    • 7.1.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.1.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.1.5. All Genetic testing-Volumes, Prices, Revenues
  • 7.2. Japan
    • 7.2.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.2.2. Predictive Testing-Volumes, Prices, Revenues
    • 7.2.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.2.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.2.5. All Genetic testing-Volumes, Prices, Revenues
  • 7.3. South Korea
    • 7.3.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.3.2. Predictive Testing-Volumes, Prices, Revenues
    • 7.3.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.3.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.3.5. All Genetic testing-Volumes, Prices, Revenues
  • 7.4. India
    • 7.4.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.4.2. Predictive Testing-Volumes, Prices, Revenues
    • 5.1.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.4.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.4.5. All Genetic testing-Volumes, Prices, Revenues
  • 7.5. Australia
    • 7.5.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.5.2. Predictive Testing-Volumes, Prices, Revenues
    • 7.5.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.5.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.5.5. All Genetic testing-Volumes, Prices, Revenues
  • 7.6. Rest of Asia Pacific
    • 7.6.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 7.6.2. Predictive Testing-Volumes, Prices, Revenues
    • 7.6.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 7.6.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 7.6.5. All Genetic testing-Volumes, Prices, Revenues

8. Country Markets-Latin America, Africa & The Middle East

  • 8.1. Brazil
    • 8.1.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 8.1.2. Predictive Testing-Volumes, Prices, Revenues
    • 8.1.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 8.1.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 8.1.5. All Genetic testing-Volumes, Prices, Revenues
  • 8.2. Mexico
    • 8.2.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 8.2.2. Predictive Testing-Volumes, Prices, Revenues
    • 8.2.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 8.2.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 8.2.5. All Genetic testing-Volumes, Prices, Revenues
  • 8.3. Rest of Latin America
    • 8.3.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 8.3.2. Predictive Testing-Volumes, Prices, Revenues
    • 8.3.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 8.3.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 8.3.5. All Genetic testing-Volumes, Prices, Revenues
  • 8.4. Africa & The Middle East
    • 8.4.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 8.4.2. Predictive Testing-Volumes, Prices, Revenues
    • 8.4.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 8.4.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 8.4.5. All Genetic testing-Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1. Global Market
    • 9.1.1. Prenatal and Newborn Testing-Volumes, Prices, Revenues
    • 9.1.2. Predictive Testing-Volumes, Prices, Revenues
    • 9.1.3. Pharmacogenomics Testing-Volumes, Prices, Revenues
    • 9.1.4. Direct to Consumer Testing-Volumes, Prices, Revenues
    • 9.1.5. All Genetic testing-Volumes, Prices, Revenues

10. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2019 laboratory Fees Schedule
  • II. Methodology
    • II.1. Authors
    • II.2. Sources
Back to Top